KBC Group NV Acquires 639,985 Shares of Pfizer Inc. (NYSE:PFE)

KBC Group NV boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 26.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,105,433 shares of the biopharmaceutical company's stock after purchasing an additional 639,985 shares during the period. KBC Group NV owned about 0.05% of Pfizer worth $89,872,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the second quarter valued at $29,000. Quarry LP purchased a new position in shares of Pfizer during the 2nd quarter valued at $31,000. Financial Connections Group Inc. bought a new position in shares of Pfizer during the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC purchased a new stake in Pfizer in the 1st quarter worth about $37,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock traded down $0.14 during mid-day trading on Thursday, hitting $26.58. 19,792,133 shares of the company traded hands, compared to its average volume of 37,695,891. The stock has a fifty day moving average price of $28.76 and a 200-day moving average price of $28.67. The stock has a market cap of $150.63 billion, a price-to-earnings ratio of 35.74, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. During the same period last year, the firm posted ($0.17) EPS. Pfizer's revenue for the quarter was up 31.2% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.32%. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a "buy" rating to a "strong-buy" rating in a research note on Tuesday. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price target for the company. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $33.58.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.